HEPATOCELLULAR carcinoma (HCC) is the most common type of primary liver cancer, accounting for up to 90% of cases worldwide. Fucoidan Enhances TACE Outcomes in Hepatocellular CarcinomaRecent research has investigated whether low-molecular-weight fucoidan (LMF), a compound derived from brown seaweed, could enhance the efficacy of TACE. In a randomised, double-blind, placebo-controlled trial, patients with unresectable hepatocellular carcinoma received either TACE alone or TACE with LMF supplementation. These results introduce a new perspective on the management of hepatocellular carcinoma, challenging the view that TACE should be used in isolation. Fucoidan improves tumour control and liver function in TACE for unresectable hepatocellular carcinoma: a randomised trial.